EBOVAC-Salone Extension Study – EBL3005

The EBOVAC-Salone Extension Study (EBL3005) is designed to prolong the follow-up of participants in a previous study (the EBOVAC-Salone trial-EBL3001) to a total period of four to five years for each participant.

In the EBOVAC-Salone trial, under EBOVAC1, participants were vaccinated with either: (a) the 2-dose Ebola vaccine regimen of Ad26.ZEBOV followed by MVA-BN®-Filo administered 56 days later; or (b) a quadrivalent meningococcal vaccine. They were then followed up for one year (children, aged 1 to 17 years), or for two to three years (adults). The participants who received at least one Ebola vaccine in the EBOVAC-Salone trial are eligible to take part in the EBOVAC-Salone Extension Study. The purpose of the EBOVAC-Salone Extension Study is to evaluate the long-term safety and immunogenicity of the two-dose vaccine regimen, up to four years after vaccination (in those aged 1 to 17 years at the time of vaccination), or up to five years after vaccination (in adults).

The Extension study also includes children of female EBOVAC-Salone participants, who were conceived either (a) during the 3-month period following vaccination with Ad26.ZEBOV, or (b) during the 28-day period following vaccination with MVA-BN®-Filo.

Study Activities

Collaborators and partners in the EBOVAC-Salone Extension Study include:

These projects have received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement EBOVAC1 (grant nr. 115854), EBOVAC2 (grant nr. 115861), EBOVAC3 (grant nr. 800176), EBOMAN (grant nr. 115850) and EBODAC (grant nr. 115847). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and European Federation of Pharmaceutical Industries and Associations (EFPIA).
Copyright © 2020 Ebovac | Terms and Conditions | WordPress development by Toast.